Acquiring Company
Ambrose Healthcare
Acquired Company
AM-Pharma
United Kingdom
UtrechtBiotechnologyHealth CareTherapeuticsPharmaceuticalBiotechnologyPharmaceuticalDescription
Ambrose Healthcare has acquired 100% of the shares of Dutch pharma company AM-Pharma. The deal gives Ambrose rights to ilofotase alfa, an investigational enzyme replacement therapy for hypophosphatasia, and an established base in Utrecht, Netherlands. AM-Pharma shareholders may receive up to €161m in upfront and milestone payments, plus royalties on future sales.
Quick answer
Ambrose Healthcare is acquiring AM-Pharma, announced October 20, 2026. Ambrose Healthcare is based in United Kingdom.
- How much did Ambrose Healthcare pay for AM-Pharma?
- The deal value was not disclosed.
- What does Ambrose Healthcare do?
- Ambrose Healthcare is a British pharmaceutical company developing rare disease therapies.
- Where are Ambrose Healthcare and AM-Pharma based?
- Ambrose Healthcare is based in United Kingdom. AM-Pharma is based in Utrecht, Utrecht, Netherlands.
Source: Fundz verified event record.
Other recent acquisitions in Therapeutics and Pharmaceutical
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Nuformix proposes merger with Biovara (November 11, 2026)
- Abeona Therapeutics to Acquire APT-1011 Assets from Ellodi Pharmaceuticals (November 9, 2026)
- Acrivon Therapeutics Acquires Aqilion’s Drug Development Programs (November 6, 2026)
- Indivior Pharmaceuticals Completes Acquisition of Supernus Pharmaceuticals (November 2, 2026)
- Pelthos to merge with Castle Creek Biosciences (October 30, 2026)
- Merck KGaA to acquire Silence Therapeutics for $1.3B, $1.3B (October 19, 2026)
Who to call at Ambrose Healthcare, and when
When Ambrose Healthcare changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Ambrose Healthcare raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Ambrose Healthcare, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Ambrose Healthcare. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Ambrose Healthcare makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Frequently asked
Who acquired AM-Pharma?
AM-Pharma was acquired by Ambrose Healthcare, based in United Kingdom. The deal was reported on October 20, 2026. Ambrose Healthcare is a British pharmaceutical company developing rare disease therapies. Ambrose Healthcare is privately held and operates in Biotechnology.
When did Ambrose Healthcare acquire AM-Pharma?
Ambrose Healthcare's acquisition of AM-Pharma was reported on October 20, 2026. Ambrose Healthcare has acquired 100% of the shares of Dutch pharma company AM-Pharma. The deal gives Ambrose rights to ilofotase alfa, an investigational enzyme replacement therapy for hypophosphatasia, and an established base in Utrecht, Netherlands. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does AM-Pharma do?
AM-Pharma is a Dutch pharmaceutical company developing enzyme replacement therapies for rare diseases. Its lead investigational asset is ilofotase alfa for hypophosphatasia, which is in Phase II-ready development. It is privately held, operating in Biotechnology, and is based in Utrecht.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.